Neuron Specific Enolase (Nse) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Neuronal Damage Biomarker |
| Target |
Neuron-specific enolase (ENO2) |
| Sample Type |
CSF, Blood (serum/plasma) |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Stroke, TBI, Huntington's Disease |
| Sensitivity |
High for acute neuronal injury |
| Specificity |
Moderate (also expressed in neuroendocrine cells) |
Neuron-specific enolase (NSE), also known as enolase 2 (ENO2) or γ-enolase, is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolysis pathway. It is one of three enolase isoforms (α, β, γ), with the γγ homodimer form specific to neurons and neuroendocrine cells.
- Gene: ENO2
- Molecular Weight: ~45 kDa (each subunit, 433 amino acids)
- Chromosome: 12p13
- Expression: Primarily neurons, also neuroendocrine cells (APUD cells)
- Isoforms: α (non-neuronal), β (muscle), γ (neuronal)
NSE forms a homodimer (γγ) or heterodimer (αγ):
- Each subunit has two domains
- Catalytic site contains magnesium ion
- The γ isoform is neuron-specific
- Forms stable dimers under physiological conditions
- Glycolysis: Catalyzes 2-phosphoglycerate → phosphoenolpyruvate
- Neuronal survival: May have neuroprotective properties
- Cell signaling: Can act as a neurotrophic factor
- Stress response: Released under neuronal stress conditions
- CSF elevations: Elevated NSE levels correlate with disease severity (Palumbo et al., 2018)
- Neuronal loss: Reflects ongoing neuronal degeneration
- Disease progression: Higher levels in moderate to severe AD
- Diagnostic utility: Moderate - elevated in AD but also other conditions
- Combination panels: Often combined with tau and Aβ42
- CSF elevations: Elevated in PD patients vs. healthy controls (Santos et al., 2020)
- Disease correlation: Correlates with disease duration and Hoehn & Yahr stage
- Progression marker: Potential for disease progression monitoring
- Differential diagnosis: Lower than in atypical parkinsonism (PSP, MSA)
- Dopaminergic neurons: May reflect substantia nigra pars compacta loss
- High sensitivity: Excellent marker for motor neuron degeneration
- Progression correlation: CSF NSE correlates with disease progression rate (Mitchell et al., 2019)
- Prognosis: Higher levels predict faster progression
- Multi-marker panels: Used with NfL and pNfH for comprehensive assessment
- Upper motor neuron: Reflects both upper and lower motor neuron involvement
¶ Stroke and Traumatic Brain Injury
- Acute marker: Excellent marker for acute neuronal damage
- Kinetics: Peaks within 24-48 hours post-injury
- Prognosis: Initial levels predict functional outcome (Mussack et al., 2002)
- Infarct size: Correlates with CT/MRI lesion volume
- Hemorrhagic stroke: Also elevated in intracerebral hemorrhage
- Elevated levels: Increased in premanifest and manifest HD
- CAG correlation: Correlates with CAG repeat expansion (Toborek et al., 2013)
- Disease burden: Correlates with disease burden score
- Progression: Potential for disease progression monitoring
- Therapeutic trials: Used as secondary outcome in clinical trials
- Epilepsy: Elevated following seizures, especially status epilepticus
- MS: Elevated in active demyelination
- Creutzfeldt-Jakob disease: Very high levels (CJD)
- Brain tumors: May be elevated in neuroendocrine tumors
| Method |
Sensitivity |
Use Case |
| ELISA |
~0.5 ng/mL |
Standard clinical testing |
| Chemiluminescence |
High throughput |
Clinical labs |
| Simoa |
~1 pg/mL |
Research, low abundance |
| Western blot |
Confirmation |
Research |
| Sample |
Normal |
Elevated |
Strongly Elevated |
| CSF (ng/mL) |
<10 |
10-25 |
>25 |
| Serum (ng/mL) |
<12 |
12-30 |
>30 |
NSE is released through multiple mechanisms:
- Cell lysis: Necrosis or apoptosis releases intracellular NSE
- Active secretion: May be actively secreted by stressed neurons
- Membrane damage: Following injury
- Blood-brain barrier disruption: Allows entry into circulation
¶ Limitations and Considerations
- Neuroendocrine cells: NSE also expressed in:
- Adrenal medulla
- Pancreatic islets
- Gastrointestinal endocrine cells
- Certain tumors (neuroblastoma, small cell lung cancer)
- Hemolysis: RBC lysis in serum can falsely elevate
- Non-neuronal sources: Some non-neuronal cancers produce NSE
- Acute vs chronic: Different patterns in acute injury vs. chronic disease
- Combine with other markers: Use with NfL, tau for neurodegenerative disease
- Clinical context: Must interpret with clinical findings
- Serial monitoring: Trend more informative than single value
| Biomarker |
Source |
Peak Time |
Specificity |
| NSE |
Neurons, neuroendocrine |
24-48h |
Moderate |
| UCH-L1 |
Neurons |
24-48h |
High |
| NfL |
Axons |
1-2 weeks |
Moderate |
| NfH |
Axons |
1-2 weeks |
Moderate |
| Tau |
Neurons |
1-2 weeks |
High |
- Multi-analyte panels: Combining NSE with NfL, p-tau, and other markers
- Point-of-care testing: Rapid tests for emergency use
- Longitudinal studies: Establishing progression biomarkers
- Precision medicine: Subtype-specific patterns
The study of Neuron Specific Enolase (Nse) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- NSE in Alzheimer's - PubMed
- NSE in Parkinson's - PubMed
- NSE in ALS - PubMed
- NSE in brain injury - PubMed
- NSE in Huntington's - PubMed
- ENO2 gene - NCBI Gene
- Enolase isoforms - UniProt
- NSE in neurocritical care - PubMed